First evaluation of PET-based human biodistribution and radiation dosimetry of C-11-BU99008, a tracer for imaging the imidazoline(2) binding site

Ashwin V. Venkataraman, Nicholas Keat, James F. Myers, Samuel Turton, Inge Mick, Roger N. Gunn, Eugenii A. Rabiner, Jan Passchier, Christine A. Parker, Robin J. Tyacke, David J. Nutt

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Abstract

Background
We measured whole body distribution of 11C-BU99008, a new PET biomarker for non-invasive identification of the imidazoline2 binding site. The purpose of this phase I study was to evaluate the biodistribution and radiation dosimetry of 11C-BU99008 in healthy human subjects.

Methods
A single bolus injection of 11C-BU99008 (296 ± 10.5 MBq) was administered to four healthy subjects who underwent whole-body PET/CT over 120 min from the cranial vertex to the mid-thigh. Volumes of interest were drawn around visually identifiable source organs to generate time-activity curves (TAC). Residence times were determined from time-activity curves. Absorbed doses to individual organs and the whole body effective dose were calculated using OLINDA/EXM 1.1 for each subject.

Results
The highest measured activity concentration was in the kidney and spleen. The longest residence time was in the muscle at 0.100 ± 0.023 h, followed by the liver at 0.067 ± 0.015 h and lungs at 0.052 ± 0.010 h. The highest mean organ absorbed dose was within the heart wall (0.028 ± 0.002 mGy/MBq), followed by the kidneys (0.026 ± 0.005 mGy/MBq). The critical organ was the heart wall. The total mean effective dose averaged over subjects was estimated to be 0.0056 ± 0.0004 mSv/MBq for an injection of 11C-BU99008.

Conclusions
The biodistribution of 11C-BU99008 has been shown here for the first time in humans. Our dosimetry data showed the total mean effective dose over all subjects was 0.0056 ± 0.0004 mSv/MBq, which would result in a total effective dose of 1.96 mSv for a typical injection of 350 MBq of 11C-BU99008. The effective dose is not appreciably different from those obtained with other 11C tracers.
Original languageEnglish
JournalEJNMMI Research
Volume8
DOIs
Publication statusPublished - 30 Jul 2018

Keywords

  • Biodistribution
  • Dosimetry
  • Positron emission tomography
  • C-11-BU99008
  • Imidazoline2

Fingerprint

Dive into the research topics of 'First evaluation of PET-based human biodistribution and radiation dosimetry of C-11-BU99008, a tracer for imaging the imidazoline(2) binding site'. Together they form a unique fingerprint.

Cite this